Once-Daily pill may protect blood vessels better in black kidney transplant patients

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects who self-report their race/ethnicity as Black-non-Hispanic only (which may include self-reported African ancestry as African-American, Afro-Caribbean or African) * Subjects receiving a first or second deceased donor or living donor kidney transplant at the Hospital of the University of Pennsylvania * Subjects whose body mass index (BMI) ≥19 * Subjects who are sero-positive for Hepatitis B or C positive may also be enrolled. * Subjects whose concurrent immunosuppression at the time of transplant will be (generic or brand formulation) Mycophenolate mofetil (MMF, CellCept) or mycophenolic sodium (MPS, Myfortic®), either a standard prenisone taper or an early withdrawal protocol, and induction with rabbit-antithymocyte globulin (Thymoglobulin®). Exclusion Criteria: * Subjects who are greater than 75 years old * Known hypersensitivity to Tacrolimus and hydrogenated castor oil * Subjects who are not self-described as being of Black African descent and living in the United States * Subjects who self-report their race/ethnicity as Black-Hispanic or Multiracial * Subjects who are recipients of organ transplants other than kidney * Subjects who are recipients of third time or more kidney transplants * Subjects who are HIV positive at the time of pre-transplant screening * Subjects with recurrent focal segmental glomerulosclerosis (FSGS) * Subjects with any severe medical condition (including infection or severe liver disease) requiring acute or chronic treatment that in the investigator's opinion would interfere with study participation * Subjects with WBC ≤ 2000/mm3 or ANC ≤ 1500 mm3 with PLT ≤ 75,000/mm3 or HGB \< 8 g/dL * Subjects with mental or physical conditions or known non-adherence (defined as documentation in the patient chart of multiple missed visits and/or medication doses) which in the investigator's opinion would interfere with the objectives of the study * Subjects who have been exposed to investigational therapy within 30 days prior to enrollment or five half-lives of the investigational product (whichever is greater). * Subjects with severe diabetic gastroparesis or other severe GI disturbances that could interfere with Tacrolimus absorption * Subjects who have underwent gastric bypass at any time pre transplant. * Pregnant or nursing (lactating) women subjects, where pregnancy is defined as a state of female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\> 5 mIU/ml). * Women subjects of child-bearing potential, defined as all women physiologically capable of becoming pregnant who are unwilling to use a double-barrier method of contraception, UNLESS they are * Women whose career, lifestyle, or sexual orientation preclude intercourse with a male partner * Women whose partners have been sterilized by vasectomy or other means